All In Biotech

Drug Trial Radar · NCT00404924

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,140

Actual

Start

Nov 2006

Primary completion

Oct 2009

Study completion Nov 2014

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

  • ZD6474 (vandetanib)Drug

    once daily oral tablet

  • Best Supportive CareOther

    standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Time to death in months

Locations

102 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Germantown, Tennessee

  • Research Site

    Bahía Blanca, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Fitzroy, Australia

  • Research Site

    Perth, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Tugan, Australia

  • Research Site

    Woodville South, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Antwerp, Belgium

  • Research Site

    Brussels (Woluwé-St-Lambert), Belgium

  • Research Site

    Charleroi, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Oshawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Dalian, China

  • Research Site

    Guangzhou, China

  • Research Site

    Nanjing, China

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Brest, France

  • Research Site

    Caen, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Nice, France

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.